Literature DB >> 20176612

Prevalence of kidney disease in anaemia differs by GFR-estimating method: the Third National Health and Nutrition Examination Survey (1988-94).

Michelle M Estrella1, Brad C Astor, Anna Köttgen, Elizabeth Selvin, Josef Coresh, Rulan S Parekh.   

Abstract

BACKGROUND: Anaemia worsens as kidney function declines. Both conditions are associated with increased mortality. Serum cystatin C is purportedly a more sensitive marker of kidney disease and a better predictor of mortality than serum creatinine. However, studies suggest that extrarenal factors also influence cystatin C levels.
METHODS: We determined whether estimates of glomerular filtration rate [estimated glomerular filtration rate (eGFR)] based on serum cystatin C alone or in combination with serum creatinine were superior to those based on serum creatinine in recognizing impaired kidney function in the setting of anaemia in a sub-sample of the Third National Health and Nutrition Examination Survey of the USA consisting of 6734 participants, 20 years or older.
RESULTS: The prevalence of moderate to severe kidney disease (eGFR 15-59 mL/min/1.73 m(2)) among anaemic persons was 15-16% when based on serum creatinine alone (eGFR(SCR)) or combined with cystatin C (eGFR(SCR) (+) (CYSC)); this estimate increased to nearly 25% when kidney function was estimated by cystatin C (eGFR(CYSC)). The adjusted odds ratios of kidney disease in anaemic versus non-anaemic persons were slightly higher with eGFR(CYSC) than eGFR(SCR) and eGFR(SCR) (+) (CYSC) in younger adults [odds ratio (OR) = 5.22, 95% confidence interval (CI): 2.23, 12.17], women (OR = 5.34, 95% CI: 2.36, 12.06) and those with elevated C-reactive protein (CRP) (OR = 7.36, 95% CI: 1.98-27.36).
CONCLUSIONS: Impaired kidney function was common in individuals with anaemia. Among anaemic individuals, the prevalence estimate for kidney disease was notably higher when kidney function was estimated by cystatin C alone compared with the estimations by serum creatinine alone or in combination with serum cystatin C. eGFR(CYSC) may be particularly helpful in identifying kidney disease in the setting of anaemia among younger persons, women and those with elevated CRP. Regardless of which renal biomarker is used, our study suggests that an evaluation for underlying kidney disease should be considered in the standard workup of anaemia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20176612      PMCID: PMC2910334          DOI: 10.1093/ndt/gfq040

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  42 in total

1.  Sample design: Third National Health and Nutrition Examination Survey.

Authors:  T M Ezzati; J T Massey; J Waksberg; A Chu; K R Maurer
Journal:  Vital Health Stat 2       Date:  1992-09

2.  A clinical evaluation of serum ferritin as an index of iron stores. 1974.

Authors:  D A Lipschitz; J D Cook; C A Finch
Journal:  Nutrition       Date:  1992 Nov-Dec       Impact factor: 4.008

Review 3.  Measurement of renal function in chronic renal disease.

Authors:  A S Levey
Journal:  Kidney Int       Date:  1990-07       Impact factor: 10.612

4.  Timing of onset of CKD-related metabolic complications.

Authors:  Olivier Moranne; Marc Froissart; Jerome Rossert; Cedric Gauci; Jean-Jacques Boffa; Jean Philippe Haymann; Mona Ben M'rad; Christian Jacquot; Pascal Houillier; Benedicte Stengel; Bruno Fouqueray
Journal:  J Am Soc Nephrol       Date:  2008-11-12       Impact factor: 10.121

5.  Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.

Authors: 
Journal:  BMJ       Date:  1990-03-03

6.  Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III).

Authors:  Anna Köttgen; Elizabeth Selvin; Lesley A Stevens; Andrew S Levey; Frederick Van Lente; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2008-03       Impact factor: 8.860

7.  Prevalence of anemia among unselected adults with diabetes mellitus and normal serum creatinine levels.

Authors:  Adiv Goldhaber; Rosane Ness-Abramof; Martin H Ellis
Journal:  Endocr Pract       Date:  2009 Nov-Dec       Impact factor: 3.443

8.  Method of glomerular filtration rate estimation affects prediction of mortality risk.

Authors:  Brad C Astor; Andrew S Levey; Lesley A Stevens; Frederick Van Lente; Elizabeth Selvin; Josef Coresh
Journal:  J Am Soc Nephrol       Date:  2009-09-17       Impact factor: 10.121

9.  'Microalbuminuric anaemia'--the relationship between haemoglobin levels and albuminuria in diabetes.

Authors:  O R Adetunji; H Mani; A Olujohungbe; K A Abraham; G V Gill
Journal:  Diabetes Res Clin Pract       Date:  2009-05-29       Impact factor: 5.602

10.  Summary of a report on assessment of the iron nutritional status of the United States population. Expert Scientific Working Group.

Authors: 
Journal:  Am J Clin Nutr       Date:  1985-12       Impact factor: 7.045

View more
  4 in total

1.  Renal resistive index as an indicator of the presence and severity of anemia and its future development in patients with hypertension.

Authors:  Muneyoshi Tanimura; Kaoru Dohi; Masumi Matsuda; Yuichi Sato; Emiyo Sugiura; Naoto Kumagai; Shiro Nakamori; Tomomi Yamada; Naoki Fujimoto; Takashi Tanigawa; Norikazu Yamada; Mashio Nakamura; Masaaki Ito
Journal:  BMC Nephrol       Date:  2015-04-08       Impact factor: 2.388

Review 2.  Anemia of Inflammation with An Emphasis on Chronic Kidney Disease.

Authors:  Sajidah Begum; Gladys O Latunde-Dada
Journal:  Nutrients       Date:  2019-10-11       Impact factor: 5.717

Review 3.  Analysis of Risk Factors for Perioperative Acute Kidney Injury and Management Strategies.

Authors:  Xiang Yu; Zhe Feng
Journal:  Front Med (Lausanne)       Date:  2021-12-24

Review 4.  Complete blood count in acute kidney injury prediction: a narrative review.

Authors:  Joana Gameiro; José António Lopes
Journal:  Ann Intensive Care       Date:  2019-08-06       Impact factor: 6.925

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.